• Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • White paper
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
Inhalation
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • White paper
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact

Arkiv: Financial reports

Delårsrapport andra kvartalet 2020

Posted 26 augusti 2020 in

Read more

Delårsrapport första kvartalet 2020

Posted 07 maj 2020 in

Read more

Årsredovisning 2019

Posted 20 april 2020 in

Read more

Bokslutskommuniké 2019

Posted 20 februari 2020 in

Read more

Bokslutskommuniké 2018

Posted 27 november 2019 in

Read more

Delårsrapport tredje kvartalet 2019

Posted 14 november 2019 in

Read more

Delårsrapport andra kvartalet 2019

Posted 22 augusti 2019 in

Read more

Delårsrapport första kvartalet 2019

Posted 16 maj 2019 in

Read more

Delårsrapport första kvartalet 2019

Posted 16 maj 2019 in

Read more

Årsredovisning 2018

Posted 15 april 2019 in

Read more
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • »

Categories

  • Okategoriserade
  • PreciseInhale® – in vivo exposure
  • PreciseInhale® – Isolated Perfused Lung (IPL)
  • PreciesInhale® – Clinic
  • DissolvIt® – Dissolution tests
  • XposeALI® – Cell culture exposure

Archive

  • september 2022
  • maj 2022
  • april 2022
  • mars 2022
  • februari 2022
  • november 2021
  • juni 2021
  • mars 2021
  • december 2020
  • juni 2020
  • mars 2020
  • december 2019
Contact

Hälsovägen 7
Novum Floor 6, Elevator E
141 57 Huddinge, Sweden.
contact@inhalation.se
+46 (0) 705 625 195

Visitor entrance: Blickagången 6, Floor 6, Elevator E

Useful links
  • Inhalation Research Services
    • Efficacy studies/ Disease models
    • Formulation
    • PK studies
      • Aerosol characterization
      • In vivo PK studies
      • Ex vivo Isolated Perfused Lung method
      • In vitro dissolution tests – DissolvIt
      • In vitro cell permeability tests
    • Toxicology studies
    • Combination product development/ Device selection/ CMC data
  • Instruments
    • PreciseInhale®
      • Precision dosing
      • PreciseInhale® input: Inhaler
      • PreciseInhale® input: Nebulizer
    • DissolvIt ®
    • XposeALI ®
    • Nose-Only
    • Intratracheal
    • Technical specifications
  • Publications
  • White paper
  • Webinars
  • About
    • About Us
    • Our Customers
    • Our Team
    • Management
    • Board
    • Advisory Board
  • Investors / investerare
    • Bolagsanalys
    • Pressmeddelanden
    • Prenumerera
    • IPO 2017
    • Finansiering
    • Finansiella rapporter
    • Kalender
    • Ägarlista
    • Bolagstämma
    • Bolagsstyrning
    • Presentationer
  • Contact
About Us

Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.

Privacy policy

Copyright © 2026 Inhalation. All rights reserved.

Design mkmedia
Contact us!
To top